Mollica V.; Rizzo A.; Massari F., Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 559 - 560 [articolo]
Di Nunno V.; Santoni M.; Gatto L.; Mollica V.; Massari F., Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 390 - 390 [articolo]
Rizzo A.; Mollica V.; Massari F., Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065, «JOURNAL OF CLEANER PRODUCTION», 2020, 78, pp. 205 - 206 [articolo]
Rizzo A.; Mollica V.; Massari F., Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 806 - 806 [articolo]
Rizzo A.; Mollica V.; Massari F., Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 804 - 805 [articolo]
Massari, F; Mollica, V, Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations, «EUROPEAN UROLOGY», 2020, 78, pp. 768 - 770 [articolo]
Mollica V.; Rizzo A.; Massari F., Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 561 - 562 [articolo]
Santoni M.; Heng D.Y.; Bracarda S.; Procopio G.; Milella M.; Porta C.; Matrana M.R.; Carteni G.; Crabb S.J.; De Giorgi U.; Basso U.; Masini C.; Calabro F.; Vitale M.G.; Santini D.; Massari F.; Galli L.; Fornarini G.; Ricotta R.; Buti S.; Zucali P.; Caffo O.; Morelli F.; Carrozza F.; Martignetti A.; Gelibter A.; Iacovelli R.; Mosca A.; Atzori F.; Vau N.; Incorvaia L.; Ortega C.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Paolucci V.; Graham J.; Pierce E.; Scagliarini S.; Sepe P.; Verzoni E.; Merler S.; Rizzo M.; Sorgentoni G.; Conti A.; Piva F.; Cimadamore A.; Montironi R.; Battelli N., Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors, «CANCERS», 2020, 12, Article number: 84, pp. 1 - 13 [articolo]Open Access
Aurilio G.; Santoni M.; Cimadamore A.; Massari F.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Battelli N.; Nole F.; Montironi R., Renal Cell Carcinoma: genomic landscape and clinical implications, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2020, 5, pp. 95 - 100 [articolo]
Loriot, Y.; Sternberg, C. N.; Castellano, D.; Oosting, S. F.; Dumez, H.; Huddart, R.; Vianna, K.; Gordoa, T. A.; Skoneczna, I.; Fay, A. P.; Nole, F.; Massari, F.; Brasiuniene, B.; Maroto, P.; Fear, S.; Di Nucci, F.; de Ducla, S.; Choy, E., Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma, «EUROPEAN JOURNAL OF CANCER», 2020, 138, pp. 202 - 211 [articolo]
Massari F.; Mollica V.; Rizzo A.; Cosmai L.; Rizzo M.; Porta C., Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis, «EXPERT OPINION ON DRUG SAFETY», 2020, 19, pp. 1329 - 1338 [articolo]
Giunchi F.; Franceschini T.; Gruppioni E.; Altimari A.; Capizzi E.; Massari F.; Schiavina R.; Brunelli M.; Martignoni G.; Fiorentino M., Similarities and differences between clear cell tubulo-papillary and conventional clear cell renal cell carcinoma: A comparative phenotypical and mutational analysis, «DIAGNOSTICS», 2020, 10, Article number: 123, pp. 123 - 123 [articolo]Open Access
Di Nunno V.; Santoni M.; Mollica V.; Conti A.; Montironi R.; Battelli N.; Ardizzoni A.; Massari F., Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients, «CLINICAL DRUG INVESTIGATION», 2020, 40, pp. 211 - 226 [articolo]
Mollica V.; Rizzo A.; Massari F., The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer, «FUTURE ONCOLOGY», 2020, 16, pp. 2029 - 2033 [articolo]
Cimadamore A.; Aurilio G.; Nole F.; Massari F.; Scarpelli M.; Santoni M.; Lopez-Beltran A.; Cheng L.; Montironi R., Update on circulating tumor cells in genitourinary tumors with focus on prostate cancer, «CELLS», 2020, 9, Article number: 1495, pp. 1 - 18 [articolo]Open Access
